Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
20,761,963
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
275,894
-
Shares change
-
-68,714
-
Total reported value, excl. options
-
$1,981,066
-
Value change
-
-$338,820
-
Put/Call ratio
-
56.52%
-
Number of buys
-
3
-
Number of sells
-
-9
-
Price
-
$7.16
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q4 2023
22 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q4 2023.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 275,894 shares
of 20,761,963 outstanding shares and own 1.33% of the company stock.
Largest 10 shareholders include Wellington Shields Capital Management, LLC (133,146 shares), Wellington Shields & Co., LLC (43,091 shares), RENAISSANCE TECHNOLOGIES LLC (29,100 shares), GEODE CAPITAL MANAGEMENT, LLC (22,221 shares), FRANKLIN RESOURCES INC (19,743 shares), CITADEL ADVISORS LLC (12,916 shares), JANE STREET GROUP, LLC (12,538 shares), MORGAN STANLEY (1,453 shares), UBS Group AG (1,222 shares), and BlackRock Inc. (296 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.